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 CURRENTOPINION Critical aspects to achieve a high-quality
melanoma clinic
Reinhard Dummera, Egle Ramelytea,b, Mitch Levesquea,
Simone M. Goldingera, and Ralph P. Brauna
Purpose of review
With incidence of melanoma growing worldwide and new therapies prolonging the survival of patients
with advanced disease, complex medical care is needed.
Recent findings
Best care of complicated melanoma cases is achieved in specialized referral centers. Aims to provide
optimized melanoma therapy, best patient-reported treatment outcome, and successful clinical and
translational research, necessitate a dedicated interdisciplinary team.
Summary
We report on critical aspects of the interaction between patients, medical care givers, clinical trial and
biobanking teams, and emphasize the importance of interdisciplinary tumor boards. Specialized skin
cancer nurses and local patient advocacy groups should be involved in patient care and could be the
binding link between the patients and the treatment team.
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INTRODUCTION
Even in the era of novel therapies, melanoma
remains the cause of the majority of skin cancer-
related deaths and hence remains the focus of
experimental, preclinical, and clinical research.
Accounting for less than 2% of skin cancer cases
[1], it has a 5-year overall survival (OS) rate of 95–
100% in stage I, 65–82.8% in stage II, 41–71% in
patients with lymph-node involvement (stage III),
and 9–28% in patients with distant metastases
(stage IV) [2].
Melanoma has a rather heterogeneous molecu-
lar pattern of alterations, and comprises a group
of malignancies, which originate from epidermal
melanocytes or nevi, derived from the neural
crest cells. About half harbor somatic activating
mutations in the BRAF gene, 28% in NRAS, and
14% have an inactivating mutation in the neuro-
fibromatosis (NF)1 gene, which encodes a tumor
suppressor affecting mitogen-activated protein
kinase (MAPK) signaling. In cutaneous melanomas,
ultraviolet (UV) signature mutations are common
and are noted in 93.5% of RAS mutated, 92.0%
ofNF1mutated, 90.7% of BRAFmutated, and, inter-
estingly, only 30% of triple wild-type melanomas.
Yet, the latter group shows more complex structural
arrangements and copy-number changes [3]. Cell
proliferation cascade seems to have multiple inter-
connected points, with a good example being the
co-occurrence of mutations in NF1 and other RAS-
opathy genes, such as RASA2, SOS1, PTPN11, RAF1,
which effect RAS-MAPK signaling [4].
The origin and the pathogenesis of other less
frequent melanoma types such as malignant blue
nevus or spitzoid melanomas are less clear. These
neoplasms have a special biology, therefore typical
prognostic hallmarks such asmitotic activity, tumor
thickness, and even the presence of small metastases
in the locoregional lymph node should have less
impact on the therapeutic strategy [5]; however,
genetic markers, such as the TERT promoter
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mutations, might help to discriminate between life
threatening and harmless spitzoid lesions [6].
MELANOMA THERAPY TODAY
In early stages, surgical removal of the primary
tumor and in-transit or lymph node metastases
is the backbone of the therapeutic strategy. Several
well-designed clinical trials comparing surgical
approaches such as safety margins (1–5 cm)
[7–11] or lymph node dissection versus follow-up
in case of microscopic involvement [12
&
], have
justified a patient-friendly and risk-adapted surgical
management plan [7,13,14]. With the introduction
of powerful systemic therapies in the adjuvant
setting [15,16
&
] and the development of intrale-
sional therapies, such as talimogene laherperepvec
(T-VEC) [17
&
], the role of surgerymight change even
more in the future. The gray zone between surgery,
irradiation, intralesional, and systemic therapy
is critical and deserves special attention with an
intensive interdisciplinary discussion.
The landscape of effective treatment options has
changed dramatically over the last 6 years with the
approval of nine drugs for advanced melanoma by
the Food and Drug Administration (FDA) and
European Medicines Agency (Fig. 1). Kinase BRAF
inhibitors (BRAFi; vemurafenib and dabrafenib),
MEK inhibitors (MEKi; trametinib and cobimetinib)
[18,19], and immune response modulating agents
[anti-CTLA-4 (ipilimumab) and anti-PD-1 anti-
bodies (nivolumab and pembrolizumab)] [20–25]
show better response rates than seen with earlier
therapies, and increase the likelihood of longer
survival in patients with advanced melanoma.
Recently, the only approved adjuvant therapy
was interferon (IFN)-a, which showed improved
relapse-free survival (RFS), but with small impact
on OS [15]. Recent data of ipilimumab used in an
adjuvant setting was shown to improve RFS as
well as OS, when compared with placebo [16
&
],
and is already approved in the United States for that
indication [26], whereas European approval is still
pending. Adjuvant trials investigating vemurafenib,
the combination of dabrafenib/trametinib, and
the immune therapeutics pembrolizumab and nivo-
lumab have been recruited, but they will need
additional years before the results are available.
There is no strong consensus regarding the treat-
ment of unresectable local disease. Radiotherapy,
electrochemotherapy, isolated limb perfusion, or
intralesional approaches, such as T-VEC, interleukin
(IL)-2, or destructive therapies can be considered
[7,14,27], whereas in unresectable metastatic dis-
ease, first-line treatment with PD-1 checkpoint
inhibitor, alone or in combination with CTLA-4
inhibitor independent of BRAF mutation status is
recommended [14].
Clinical trials with BRAFi in patients harboring
BRAF mutations showed a clear improvement of
progression-free survival (PFS) as well as OS [28–
30] and were followed by trials comparing combi-
nation therapy with BRAFi and MEKi with BRAFi
KEY POINTS
 A multidisciplinary approach is needed to provide high-
quality care to melanoma patients.
 A tumor board creates a space for the discussion of
patient cases and for creating treatment SOPs for
certain cases.
 A patient advocacy group with cancer nurse should be
a part of a high-quality melanoma center.
FIGURE 1. Timeline of FDA and EMA approved and pending immunotherapy and targeted therapy. BRAFi encorafenib
is to be approved in 2017. EMA, European Medicines Agency; FDA, Food and Drug Administration; IFN-a, interferon-a; IL-2,
interleukin-2; T-VEC, talimogene laherperepvec.
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monotherapy. Latest efficacy report from a clinical
trial comparing the combination of vemurafenib
and cobimetinib with vemurafenib monotherapy
showed a median OS of 22.3 months [95% confi-
dence interval (CI) 20.3–not estimable] in the first
group and 17.4 months (95% CI 15.0–19.8) in the
monotherapy group [hazard ratio 0.70 (95% CI
0.55–0.90), P¼0.005] and a 2-year OS of 48.3 and
38.0%, respectively [31
&
]. Combination of new
BRAFi encorafenib and MEKi binimetinib clearly
showed improved median PFS of 14.9 versus 7.3
months in vemurafenib group [32
&
]. Based on such
results, BRAFi monotherapy is no longer advised,
thus these drugs must be given in combination
with MEKi whenever possible [14].
Despite these promising data, up to 50% of
patients do not respond to immunotherapy [20]
and about half of the patients who have achieved
a clinical response (partial or complete) under
a combination of kinase inhibitors eventually
develop acquired drug resistance that leads to
disease progression [31
&
,33]. This remains an urgent
unmet need for further treatment options for those
patients as well as patients who harbor mutations
in genes besides BRAF or NRAS.
ESSENTIAL NEEDS: INTERDISCIPLINARY
TEAM AND TUMOR BOARDS IN HIGH-
QUALITY MELANOMA CENTERS
In an ideal situation, the whole spectrum of
medical information including cutting edge science
should be considered during the process of clinical
decision-making. Early stage melanomas can be
treated by a single medical specialty such as derma-
tology or plastic surgery. However, even in these
cases high-quality care in dermatology with exper-
tise in dermoscopy of pigmented skin lesions,
surgery, and high-quality dermato-pathology is
mandatory.
As soon as special anatomic regions such as the
head and neck are involved, several surgical subspe-
cialists are needed to achieve an optimized surgical
approach. The complexity is further increased if
sentinel lymph node biopsy (SNB) is indicated. SNB
results have amajor impact on the patients’ manage-
ment; therefore, this procedure should be restricted
to centers of excellence that follow high-quality
standard operating procedures (SOPs) (Table 1).
The situation gets even more complex in
advanced disease stages necessitating an interdis-
ciplinary approach involving many specialties
(dermatology, radiology, nuclear medicine, radio-
oncology, neurosurgery, visceral surgery, plastic
surgery, ear-nose-throat, pathology, psycho-oncol-
ogy, etc.). Involving so many different medical spe-
cialties requires a platform wherein individual
patients are discussed among all diverse specialists
and a consensus decision regarding the manage-
ment procedures is reached.
In ouropinion the best forum for this exchange is
a multidisciplinary tumor board. Patient cases,
including clinical images, pathology slides and Pic-
ture Archiving and Communication System (PACS)
images [computed tomography (CT) scans, PET CTs,
MRIs, etc.], molecular data, and clinical features can
be discussed and reviewed by the members of the
board. Because not all physicians who participate
in the board see the patient, it is important that
thedecisionmadeby the tumorboard is documented
in a central electronic chart system and is automati-
cally communicated to the major care providers
of the patients outside the hospital. This ensures that
the decisions of the board will be visible for everyone
treating the patient in the future. As stage IV mela-
noma patients will be treated by different specialists
and will require one treatment before another, it is
also important to define the key leading physician,
who will follow up on the working plan.
From our experience with tumor boards, we
know that for some situations it is difficult to reach
a consensus since some specialists might have differ-
ent opinions regarding the treatment of a patient.
This provides a unique opportunity to elaborate an
evidence-based SOP for this situation so that if the
next patient comes with the same problem there will
Table 1. Quality criteria for sentinel lymph node biopsy
Histology of the primary tumor should be reevaluated and provided for comparison with the sentinel lymph node (SLN)
In special forms of melanoma, such as atypical Spitz nevus, malignant blue nevus or desmoplastic melanoma, SNB has modest prognostic
relevance
Re-excision with SM and SNB should be performed simultaneously, because of change in the lymph-draining (especially in head and neck)
Marking of the scar should be done during the consultation, preferably with photo-documentation
SPECT is advised in cases of unclear SLN localization
Re-excision and SNB should be performed by an experienced surgeon
Histology of SLN should be evaluated according to cell-morphology and immune-profile of the primary tumor
SM, safety margin; SNB, sentinel lymph node biopsy; SPECT, single-photon emission computed tomography.
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be a guideline for how to proceed. This should be
elaborated outside the tumor board by a group of
representatives of all specialties involved. The result
of the consensus shouldbe approvedby themembers
of the tumor board andmade available so that every-
one can access them if needed. This type of meeting
is called Quality Circle and should be performed at
least twice a year in order to improve standardization
and the quality of care for the individual patient as
well as to foster the interdisciplinary exchange.
It is important to learn from unusual cases
(either patients who did very well, patients with a
very unusual presentation or unusual course of dis-
ease, or any other situation of special interest). The
cases should be presented and discussed in detail.
Today, the pace of increasing scientific
and clinical knowledge generation is dramatic.
It remains an open question how innovation should
be considered in the treatment decision-making. As
a general worldwide principle, physician’s advice
about the most appropriate treatment for a given
patient is well considered and based on convincing
rationale, which nowadays is more and more based
on the results of next-generation sequencing (NGS)
and biomarkers such as programmed death-ligand-1
expression; however, this decision also reflects the
physician’s inclination to innovation. Although any
physicianmay prescribe a drug, the clinical results of
which are not fully known yet, thereby believing in
the added value of a new treatment, othersmay have
the more conservative tendency to rely on existing,
well-established treatments. These reflectionsmight
be especially relevant for preclinical findings.
COLLABORATION WITH LOCAL PATIENT
ADVOCACY GROUPS
Physicians and patients may have overlapping or
divergent expectations on the outcome of cancer
therapies and on the quality of medical services.
However, there are hardly any communications
between physicians and patients about their inter-
action. As a consequence, a platform for these feed-
back communicationswouldbeuseful and advisable.
An attempt to solve this problem is a regular inter-
action between the medical team involved and the
appropriate representatives. We suggest to create a
local patient advocacy group. This group is intro-
duced to other patientswhowill use this opportunity
to communicate about their personal experiences
and to highlight positive and negative feedbacks.
IMMUNE ONCOLOGY FACULTY
Newer drugs, especially immunotherapy with
checkpoint inhibiting monoclonal antibodies,
can cause a wide spectrum of adverse events,
most of which are immune related. These require
management approaches different from those used
in conventional therapy. Anti-PD-1 monotherapy
is well tolerated in most cases with a frequency
of grade 3/4 adverse events less than 5% for all
organ systems. Anti CTLA-4 antibody ipilimumab
and ipilimumab/nivolumab combinations show
far more toxicity than anti-PD-1 monotherapy
[34].
Fortunately, most adverse events are mild,
often self-limiting or easy to treat using immune-
modulating agents when identified early. How-
ever, severe adverse events can evolve into life-
threatening critical situations and hence need
special attention. Since more or less every organ
system may be affected, there is a need for the
integration of multiple disciplines in adverse
event management. In our opinion, dermatology,
neurology, ophthalmology, endocrinology, hepa-
tology, and gastro-intestinology are of central
relevance followed by hematology and rheumatol-
ogy. In large hospitals, it is typically not realistic
to inform whole teams about the specific needs
during adverse event management. Therefore, it is
plausible to define an individual faculty member
in each department who is the principle contact
person who serves for the full cancer center in his
or her area of expertise.
The role of nurses during systemic therapy is
particularly noteworthy. Nurses may be very well
integrated in the treatment processes and be given
major responsibilities, especially in keeping regular
contact with patients regarding adverse events,
which can occur at any time during the treatment.
For many patients the inhibition threshold is lower
to phone a nurse than a doctor, hence nurses could
provide open and easy contact to the treatment
team. It is mandatory that the nurse is familiar
with the peculiar adverse event spectrum and the
timing of the adverse events during the applied
therapies.
BIOBANKING
The establishment of a well-managed biobank
is an essential component of a highly effective
melanoma clinic because it provides the basic infra-
structure for conducting clinical trials and is the
foundation of a cutting-edge translational oncol-
ogy research programme. However, in order to
ensure reproducibility and the most effective use
of biological samples, biobank teamsmust be cross-
trained in all preservation techniques, and clear
SOPs need to be strictly implemented, maintained,
and updated.
Melanoma and other skin neoplasms
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The choice of what samples to collect and how
to preserve them depends largely on local ethical
review boards, patient consent, the kinds of clinical
trials being run, and the available resources for
treating and storing samples. A thorough biobank-
ing programme will include blood samples and
tumor biopsies, but how these are further processed
depends largely on the intended downstream appli-
cations. Obviously, there should be a strong prefer-
ence for preservation techniques that allow for
diverse experiments subsequent to storage. Histori-
cally, tumor material has been kept mostly in for-
malin fixed paraffin embedding (FFPE), and
although DNA and RNA extraction techniques have
recently improved from FFPE tissues, many exper-
iments such as fluorescence-activated cell sorting or
cell line culturing are no longer efficient or possible
once a tumor has been preserved in FFPE.
A melanoma biobank that includes FFPE
samples but that also cultures live cells from
surplus material [35] can provide an excellent
resource for subsequent mechanistic studies. Here
it is also critical that there is effective communi-
cation between clinical and translational research
teams to make the best use of the material. For
instance, attending physicians may know import-
ant details about individual patient progression
patterns that are directly relevant for subsequent
scientific studies. Not only does such knowledge
help scientists choose the best samples for
their experiments, but it also helps focus transla-
tional research projects on the most clinically
relevant problems.
The advent of NGS technologies and increas-
ingly more specific molecular pathway inhibitors
promise a new era of precision medicine with indi-
vidualized therapies that are more effective than
previous broad-spectrum approaches to fighting
cancer. However, the high-dimensional datasets
produced by whole-exome or whole-genome
sequencing as well as RNA sequencing or even pro-
teomic approaches [36,37] introduce a new set of
problems for clinicians. Molecular tumor boards are
intended to solve that problem by reducing high-
dimensional datasets (for instance from whole-
exome sequencing) to an actionable list of targets
and approved drugs that may be readily available for
therapeutic interventions.
Although it is clear that molecular tumor boards
should be implemented to provide clinical decision
support, there are still few examples of effective
use of NGS data in routine clinical practice.Whereas
the integration of these datasets in a tumor board
setting is necessary in the future, a great deal of
work needs to be done to first, collect data from
multiple omics platforms (e.g., gene expression,
copy-number alterations, single nucleotide poly-
morphisms, mutation burden, HLA-type, T-cell
receptor repertoire, proteomics, etc.); second, define
standard, robust bioinformatics pipelines with
documentation; third, curate databases of drug–
gene interactions for clinical practice; and finally,
reduce the relevant data into simple but accurate
reports for a clinical audience.
As our understanding of molecular pathways
improves along with our ability to target them,
molecular tumor boards will become even more
useful and ubiquitous. Because of the complex
and evolving nature of the task, interdisciplinary
teams of experts must meet regularly to develop
protocols and optimize them to provide the best
possible care to melanoma patients according to the
latest scientific developments.
CONCLUSION
Modern melanoma management is a paradigm for
precision medicine in a rapidly evolving scientific
environment. Networking and cooperative projects
with basic research on a local, national, and inter-
national level are crucial. It is especially attractive to
include well-established local basic research groups
and search for cooperative projects including the
investigation of patient samples collected in the
biobank. Clinical research with pharma-sponsored
and investigator-initiated clinical trials is necessary
to create a critical understanding of clinical science.
Patients should be regularly informed about these
projects and may even actively support these
efforts.
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